Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)

PURPOSE: To determine whether six cycles of FEC3-D3 has a comparable efficacy to eight of AC4-D4. METHODS: The enrolled patients (pts) were clinically diagnosed with stage II or III breast cancer. The primary endpoint was a pathologic complete response (pCR), and the secondary endpoints were 3 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Inhwan, Kim, Jeong Eun, Jeong, Jae Ho, Ahn, Jin-Hee, Jung, Kyung Hae, Son, Byung Ho, Kim, Hak Hee, Shin, Junyoung, Lee, Hee Jin, Gong, Gyungyub, Kim, Sung-Bae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361883/
https://www.ncbi.nlm.nih.gov/pubmed/37365483
http://dx.doi.org/10.1007/s10549-023-06971-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361883/
https://www.ncbi.nlm.nih.gov/pubmed/37365483
http://dx.doi.org/10.1007/s10549-023-06971-7

Ejemplares similares